Q2 2022 EPS Estimates for BioXcel Therapeutics, Inc. Increased by Analyst (NASDAQ:BTAI)

BioXcel Therapeutics, Inc. (NASDAQ:BTAIGet Rating) – Investment analysts at Jefferies Financial Group raised their Q2 2022 earnings estimates for BioXcel Therapeutics in a note issued to investors on Monday, May 9th. Jefferies Financial Group analyst C. Howerton now forecasts that the company will post earnings of ($1.32) per share for the quarter, up from their prior forecast of ($1.40). Jefferies Financial Group also issued estimates for BioXcel Therapeutics’ Q3 2022 earnings at ($1.50) EPS, Q4 2022 earnings at ($1.54) EPS, FY2022 earnings at ($5.47) EPS, FY2023 earnings at ($6.08) EPS, FY2024 earnings at ($5.71) EPS, FY2025 earnings at ($5.59) EPS and FY2026 earnings at ($4.42) EPS.

BioXcel Therapeutics (NASDAQ:BTAIGet Rating) last issued its quarterly earnings results on Monday, May 9th. The company reported ($1.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.21) by $0.09. During the same period last year, the company earned ($1.08) EPS.

Several other analysts also recently commented on BTAI. UBS Group reduced their target price on BioXcel Therapeutics from $88.00 to $25.00 and set a “buy” rating for the company in a research note on Wednesday, February 16th. HC Wainwright raised their target price on BioXcel Therapeutics from $130.00 to $134.00 and gave the company a “buy” rating in a research note on Thursday, April 14th. Canaccord Genuity Group reduced their target price on BioXcel Therapeutics from $84.00 to $75.00 in a research note on Friday. Truist Financial reduced their target price on BioXcel Therapeutics from $125.00 to $71.00 in a research note on Tuesday. Finally, Bank of America raised their target price on BioXcel Therapeutics from $78.00 to $80.00 and gave the company a “buy” rating in a research note on Wednesday, April 6th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $68.43.

Shares of BioXcel Therapeutics stock opened at $11.74 on Thursday. The business has a 50-day moving average price of $16.26 and a two-hundred day moving average price of $19.85. BioXcel Therapeutics has a 1-year low of $9.08 and a 1-year high of $39.00. The company has a market cap of $328.54 million, a P/E ratio of -2.85 and a beta of 1.31.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. UBS Group AG lifted its position in BioXcel Therapeutics by 34.3% in the 3rd quarter. UBS Group AG now owns 215,725 shares of the company’s stock valued at $6,548,000 after acquiring an additional 55,122 shares in the last quarter. Deutsche Bank AG lifted its position in BioXcel Therapeutics by 35.8% in the 3rd quarter. Deutsche Bank AG now owns 32,894 shares of the company’s stock valued at $999,000 after acquiring an additional 8,670 shares in the last quarter. CNA Financial Corp lifted its position in BioXcel Therapeutics by 6.3% in the 3rd quarter. CNA Financial Corp now owns 10,073 shares of the company’s stock valued at $306,000 after acquiring an additional 594 shares in the last quarter. GSA Capital Partners LLP bought a new position in BioXcel Therapeutics in the 3rd quarter valued at about $1,801,000. Finally, Alliancebernstein L.P. lifted its position in BioXcel Therapeutics by 8.2% in the 3rd quarter. Alliancebernstein L.P. now owns 1,020,255 shares of the company’s stock valued at $30,965,000 after acquiring an additional 76,995 shares in the last quarter. 49.77% of the stock is currently owned by institutional investors and hedge funds.

BioXcel Therapeutics Company Profile (Get Rating)

BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors.

Featured Stories

Earnings History and Estimates for BioXcel Therapeutics (NASDAQ:BTAI)

Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.